This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
Pembrolizumab Monotherapy for the Treatment of High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study
Lancet Oncol 2021 May 26;[EPub Ahead of Print], AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, LEM Krieger, EA Singer, DF Bajorin, P Grivas, HK Seo, H Nishiyama, BR Konety, H Li, K Nam, E Kapadia, T Frenkl, R de WitFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.